Genprex partners with U Michigan to study REQORSA plus ALK-inhibitors in ALK+ lung cancer

Genprex, Inc.

Entered Sponsored Research Agreement with Univ. of Michigan Rogel Cancer Center for TUSC2/REQORSA combo with ALK-inhibitors.
Collaboration with ALK Positive nonprofit; both share cost of the SRA.
Preclinical data (AACR Apr 2024): REQORSA induced apoptosis in alectinib-resistant EML4-ALK+ NSCLC lines.
TUSC2 overexpression via REQORSA decreased cell growth and proliferation through apoptotic pathway activation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.